Percutaneous transcatheter aortic valve implantation: Evolution of the technology

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2008.10.003 Byline: Paul T.L. Chiam (a)(b), Carlos E. Ruiz (a) Abstract: Aortic stenosis (AS) is currently the most common valvular abnormality in developed countries. The gold standard treatment of severe symptomatic AS is surgical aortic valve replacement. Mechanical valves were initially the prostheses of choice; with improvement of surgical technique and results, and increased durability of bioprosthetic valves, there has been a trend toward increasing use of bioprostheses. Concurrently, percutaneous technology has advanced exponentially, and the first human percutaneous aortic valve replacement (PAVR) became a reality in 2002. Various groups have now reported their early experiences with PAVR using different technologies. This new treatment modality is evolving very rapidly. There are currently 2 devices being used in clinical trials; several more devices have first-in-man results and others in preclinical development. It appears that PAVR will most likely become a viable option for selected patients in the near future. For these technologies to continue to improve and benefit patients, cross-specialty teamwork is vital. Treatment of severe AS will greatly evolve as these new and emerging technologies improve. Enhancement in device designs and increasing operator experience will make this technology safer and allow its application to a wider patient population. Author Affiliation: (a) Department of Cardiac and Vascular Interventional Services, Lenox Hill Heart and Vascular Institute of New York, NY (b) Department of Cardiology, National Heart Center, Singapore, Singapore Article History: Received 4 June 2008; Accepted 2 October 2008 Article Note: (footnote) The authors are solely responsible for the design and conduct of this study, all study analyses, and drafting and editing of the manuscript.